We now know how many jobs are going under the hammer at Novartis, and it’s not small.
The pharmaceutical giant confirms a report from the Swiss newspaper Tages-Anzeiger that it will cut 8,000 jobs from its 108,000 global staffers. A large segment will hit directly at the company’s headquarters in Basel, as CEO Vas Narasimhan cuts some 1,400 of the slightly more than 11,000 jobs in Switzerland.
The first phase of the work is almost complete, the company says in a statement Endpoints News† Now it’s on to phase two. In the statement, Novartis says:
Keep reading Endpoints with a free plan
Instantly unlock this story and join 144,700+ biopharma professionals reading Endpoints daily – and it’s free.